Siga Technologies Inc.

SIGA Healthcare Drug Manufacturers Specialty & Generic

Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

3.17 0.02 −0.63%
Market cap
$229.2M
P/E
0.0×
Fwd P/E
28.7×
Dividend yield
0.00%
F-score
5/9
Altman Z
14.28
Beneish M
−4.02
Dividend safety
36/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 4 2
ROE
39.94% 11.23% 11.00% (1.49%)
ROA
34.88% 10.04% 8.68% (1.36%)
ROIC
179.01% 33.78% 212.85% (14.59%)
Return on Tangible Assets
36.49% 11.88% 13.67% (1.70%)
Average Days of Receivables
5.28 12.60 17.52 48.77
Free Cash Flow per Share
1.62 0.60 0.39 (0.28)
Free Cash Flow
116.31 43.12 27.75 (20.17)
Capital Expenditures
(0.33) (0.35) — —
Other line items
Cash ROIC
30.98% 12.19% 9.34% (7.13%)
Accounts Receivable Turnover
23.63 7.74 16.05 7.86
Accounts Payable Turnover
12.98 27.44 8.62 23.31
Inventory Turnover
0.74 0.60 0.56 0.64
Average Days of Payables
44.97 10.13 70.86 13.56
Days of Inventory on Hand
428.98 602.78 634.73 612.62
Tax Rate
(0.23) (0.23) (0.25) (0.49)
Research and Development Expense of Revenue
10.60% 21.10% 21.80% 38.08%
Selling, General and Administrative Expense of Revenue
13.27% 22.43% 21.55% 37.03%
Share Based Compensation of Revenue
2.13% 3.89% 3.77% 6.54%
Operating CF/Net income
1.57 1.87 1.37 7.24
Depreciation/Fixed assets
0.46 0.52 0.34 0.39
Capex/Depreciation
(0.61) (0.63) 0.00 0.00
Revenue per Share
2.41 1.32 1.31 0.75
Operating CF per Share
1.63 0.61 0.39 (0.28)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates